Cite
MLA Citation
G. McArthur et al.. “25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study.” European journal of cancer, vol. 51, n.d., pp. S722–S723. http://access.bl.uk/ark:/81055/vdc_100030687872.0x000040